Three months after raising $500m in a series G round, Moderna Therapeutics has secured $125m as part of a collaboration agreement with Merck & Co.

US-based RNA-based vaccine developer Moderna Therapeutics has received $125m in series H funding from pharmaceutical firm Merck & Co as part of an expanded collaboration agreement. Incubated by venture capital firm Flagship Ventures in 2010, Moderna is developing therapeutics and vaccines based on messenger RNA (mRNA) molecules that target cancer and infectious, rare and cardiovascular…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.